Logo image of CANF

CAN FITE BIOPHARMA LTD-ADR (CANF) Stock Fundamental Analysis

NYSEARCA:CANF - NYSE Arca - US13471N3008 - ADR - Currency: USD

1.01  -0.02 (-1.94%)

Fundamental Rating

3

Taking everything into account, CANF scores 3 out of 10 in our fundamental rating. CANF was compared to 556 industry peers in the Biotechnology industry. While CANF seems to be doing ok healthwise, there are quite some concerns on its profitability. CANF is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

In the past year CANF has reported negative net income.
CANF had a negative operating cash flow in the past year.
CANF had negative earnings in each of the past 5 years.
CANF had a negative operating cash flow in each of the past 5 years.
CANF Yearly Net Income VS EBIT VS OCF VS FCFCANF Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

With a Return On Assets value of -86.40%, CANF is not doing good in the industry: 72.12% of the companies in the same industry are doing better.
The Return On Equity of CANF (-144.96%) is worse than 61.15% of its industry peers.
Industry RankSector Rank
ROA -86.4%
ROE -144.96%
ROIC N/A
ROA(3y)-90.8%
ROA(5y)-101.33%
ROE(3y)-164.91%
ROE(5y)-170%
ROIC(3y)N/A
ROIC(5y)N/A
CANF Yearly ROA, ROE, ROICCANF Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CANF so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CANF Yearly Profit, Operating, Gross MarginsCANF Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

6

2. Health

2.1 Basic Checks

CANF does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CANF has more shares outstanding
Compared to 5 years ago, CANF has more shares outstanding
CANF has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CANF Yearly Shares OutstandingCANF Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
CANF Yearly Total Debt VS Total AssetsCANF Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

CANF has an Altman-Z score of -25.32. This is a bad value and indicates that CANF is not financially healthy and even has some risk of bankruptcy.
CANF has a worse Altman-Z score (-25.32) than 87.05% of its industry peers.
CANF has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -25.32
ROIC/WACCN/A
WACC9.07%
CANF Yearly LT Debt VS Equity VS FCFCANF Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M

2.3 Liquidity

A Current Ratio of 4.38 indicates that CANF has no problem at all paying its short term obligations.
CANF has a Current ratio of 4.38. This is comparable to the rest of the industry: CANF outperforms 48.92% of its industry peers.
CANF has a Quick Ratio of 4.38. This indicates that CANF is financially healthy and has no problem in meeting its short term obligations.
CANF's Quick ratio of 4.38 is in line compared to the rest of the industry. CANF outperforms 50.54% of its industry peers.
Industry RankSector Rank
Current Ratio 4.38
Quick Ratio 4.38
CANF Yearly Current Assets VS Current LiabilitesCANF Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

4

3. Growth

3.1 Past

CANF shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 40.00%, which is quite impressive.
The Revenue has decreased by -9.29% in the past year.
Measured over the past years, CANF shows a very negative growth in Revenue. The Revenue has been decreasing by -19.81% on average per year.
EPS 1Y (TTM)40%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-227.27%
Revenue 1Y (TTM)-9.29%
Revenue growth 3Y-7.55%
Revenue growth 5Y-19.81%
Sales Q2Q%14.04%

3.2 Future

The Earnings Per Share is expected to grow by 50.44% on average over the next years. This is a very strong growth
CANF is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 203.73% yearly.
EPS Next Y13.95%
EPS Next 2Y50.44%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year0%
Revenue Next 2Y-10.92%
Revenue Next 3Y203.73%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CANF Yearly Revenue VS EstimatesCANF Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M 100M
CANF Yearly EPS VS EstimatesCANF Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2023 2024 2025 2026 0 200 -200 -400 -600 -800

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CANF. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CANF. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CANF Price Earnings VS Forward Price EarningsCANF Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CANF Per share dataCANF EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -200 -400 -600

4.3 Compensation for Growth

CANF's earnings are expected to grow with 50.44% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y50.44%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

CANF does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

CAN FITE BIOPHARMA LTD-ADR

NYSEARCA:CANF (7/24/2025, 4:10:02 PM)

1.01

-0.02 (-1.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-26 2025-03-26/bmo
Earnings (Next)08-28 2025-08-28
Inst Owners4.05%
Inst Owner Change0%
Ins Owners0.02%
Ins Owner ChangeN/A
Market Cap13.01M
Analysts82.86
Price Target8.2 (711.88%)
Short Float %1.03%
Short Ratio1.26
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.79%
PT rev (3m)-2.23%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)53.7%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 19.3
P/FCF N/A
P/OCF N/A
P/B 2.39
P/tB 2.39
EV/EBITDA N/A
EPS(TTM)-0.61
EYN/A
EPS(NY)-710.06
Fwd EYN/A
FCF(TTM)-0.59
FCFYN/A
OCF(TTM)-0.59
OCFYN/A
SpS0.05
BVpS0.42
TBVpS0.42
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -86.4%
ROE -144.96%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-90.8%
ROA(5y)-101.33%
ROE(3y)-164.91%
ROE(5y)-170%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 71.43%
Cap/Sales 0.74%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.38
Quick Ratio 4.38
Altman-Z -25.32
F-Score2
WACC9.07%
ROIC/WACCN/A
Cap/Depr(3y)49.68%
Cap/Depr(5y)88.86%
Cap/Sales(3y)0.71%
Cap/Sales(5y)1.36%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-227.27%
EPS Next Y13.95%
EPS Next 2Y50.44%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-9.29%
Revenue growth 3Y-7.55%
Revenue growth 5Y-19.81%
Sales Q2Q%14.04%
Revenue Next Year0%
Revenue Next 2Y-10.92%
Revenue Next 3Y203.73%
Revenue Next 5YN/A
EBIT growth 1Y0.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y9.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y9.51%
OCF growth 3YN/A
OCF growth 5YN/A